Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 13/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ATXN2 | Q99700 | 6/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11899299 | 1.00 | ENPP2 (0.38) | ENPP2KCNH2SMN1; SMN2ATXN2TNKS | |
| SCHEMBL17901213 | 0.94 | ENPP2 (0.36) | ENPP2KCNH2SMN1; SMN2ATXN2TNKS | |
| SCHEMBL11962572 | 0.94 | ENPP2 (0.36) | ENPP2KCNH2SMN1; SMN2ATXN2TNKS | |
| SCHEMBL11962597 | 0.94 | SMN1; SMN2 (0.37) | ENPP2KCNH2SMN1; SMN2ATXN2TNKS | |
| SCHEMBL170045 | 0.92 | ENPP2 (0.46) | ENPP2KCNH2ATXN2 | |
| SCHEMBL11899063 | 0.90 | PARP1 (0.36) | ENPP2KCNH2SMN1; SMN2TNKSPARP1 | |
| SCHEMBL11899062 | 0.90 | PARP1 (0.36) | ENPP2KCNH2SMN1; SMN2TNKSPARP1 | |
| SCHEMBL11899791 | 0.87 | ENPP2 (0.41) | ENPP2KCNH2ATXN2TNKSPARP1 | |
| SCHEMBL11962584 | 0.87 | ENPP2 (0.41) | ENPP2KCNH2ATXN2TNKSPARP1 | |
| SCHEMBL11899790 | 0.87 | ENPP2 (0.41) | ENPP2KCNH2ATXN2TNKSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488504-B1 | SULFOXIDE DERIVATIVES FOR TREATING TUMORS | MERCK PATENT GMBH (DE) | 2016-07-06 | — | — | EP | disclosed |
| US-8552001-B2 | Sulfoxide derivatives for the treatment of tumors | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8552001-B2 | Sulfoxide derivatives for the treatment of tumors | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8552001-B2 | Sulfoxide derivatives for the treatment of tumors | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-20120202827-A1 | SULFOXIDE DERIVATIVES FOR THE TREATMENT OF TUMORS | Merck Patent Gesellschaft mit beschrankter Hafung (DE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202827-A1 | SULFOXIDE DERIVATIVES FOR THE TREATMENT OF TUMORS | Merck Patent Gesellschaft mit beschrankter Hafung (DE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202827-A1 | SULFOXIDE DERIVATIVES FOR THE TREATMENT OF TUMORS | Merck Patent Gesellschaft mit beschrankter Hafung (DE) | 2012-08-09 | — | — | US | disclosed |
| WO-2011044978-A1 | SULFOXIDE DERIVATIVES FOR TREATING TUMORS | MERCK PATENT GMBH (DE) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202827-A1 | SULFOXIDE DERIVATIVES FOR THE TREATMENT OF TUMORS | TP53, MGMT, VHL | ENPP2 4219/4885KCNH2 3524/4885SMN1; SMN2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.